Global Bevacizumab Market – Industry Trends and Forecast to 2030

Análisis y tamaño del mercado de bevacizumab

La creciente prevalencia del cáncer y el cambio de estilo de vida, junto con los grupos de apoyo, están siendo fundamentales para que los pacientes con cáncer puedan hacer frente a la enfermedad al proporcionarles fondos y cuidados paliativos que impulsarán el crecimiento del mercado. Los mercados emergentes y la colaboración de los fabricantes farmacéuticos mundiales también tienen un impacto positivo en el mercado.                                

Data Bridge Market Research analiza que el mercado, que era de USD 6.679,14 millones en 2022, se disparará hasta USD 12.967,08 millones para 2030 y se espera que experimente una CAGR del 9,20% durante el período de pronóstico. El "cáncer" domina el segmento de enfermedades del mercado de bevacizumab debido a la creciente demanda de bevacizumab para tratar el cáncer. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de bevacizumab

Definición de mercado

El bevacizumab es un anticuerpo monoclonal recombinante humanizado que es eficaz contra el factor de crecimiento endotelial vascular llamado VEGF (citocina proangiogénica), que está formado por células que ayudan a la formación de nuevos vasos sanguíneos. El bevacizumab actúa uniéndose al VEGF y posteriormente inhibiendo su proceso de unión al receptor, lo que impide el crecimiento del tumor y de las células cancerosas. El bevacizumab se encuentra actualmente en muchos ensayos para su combinación con otros fármacos para el tratamiento del cáncer.

Dinámica del mercado mundial de bevacizumab

Conductores

• Aumento de la prevalencia del cáncer

El cáncer sigue siendo un importante problema de salud mundial y la incidencia de diversos tipos de cáncer está aumentando. El bevacizumab es el principal tratamiento para muchos tipos de cáncer, incluidos el cáncer de colon, pulmón, mama y riñón. La creciente prevalencia del cáncer en todo el mundo aumenta la demanda de bevacizumab como una opción de tratamiento eficaz, lo que impulsa el crecimiento del mercado.

• Avances en biotecnología e investigación

El campo de la biotecnología y la investigación del cáncer está evolucionando rápidamente, lo que conduce al descubrimiento de nuevos tratamientos y dianas terapéuticas. El bevacizumab, un fármaco antiangiogénico, ha demostrado ser eficaz para inhibir el crecimiento tumoral al actuar sobre la formación de vasos sanguíneos. Los continuos esfuerzos de I+D para encontrar nuevas aplicaciones y combinaciones para el bevacizumab impulsarán el crecimiento del mercado.

• Creciente inversión en centros de salud

Otro factor importante que impulsa el crecimiento del mercado es la creciente atención a la mejora de las condiciones de los centros de atención sanitaria y la mejora de la infraestructura sanitaria en general. El creciente número de asociaciones y colaboraciones estratégicas entre los actores públicos y privados en relación con la financiación y la aplicación de tecnologías nuevas y mejoradas crea otras oportunidades de mercado lucrativas.  

• Avances tecnológicos en los sistemas de administración de fármacos

The development of improved drug delivery systems has improved the delivery and efficacy of bevacizumab. For example, the introduction of intravitreal injections in treating eye diseases facilitated the use of bevacizumab in conditions such as macular degeneration and diabetic retinopathy. Technological advancements in drug delivery systems improve patient comfort and enable targeted deliveries, thus driving market growth.

Opportunities

• Growing demand in emerging markets

Emerging markets present a significant opportunity for the bevacizumab market. As healthcare infrastructure and access to advanced treatments improve in these regions, the demand for bevacizumab is expected to rise. Emerging economies, such as China, India, Brazil, and others, have a large population base and increasing incidences of cancer. By strategically entering these markets and addressing affordability challenges, companies can tap into the growing demand and expand their market share. 

• Expansion into new indications

Although bevacizumab is mainly used in treating various cancers, it can be expanded to new indications. Bevacizumab is currently being studied for its effectiveness in other diseases, such as age-related macular degeneration, diabetic retinopathy, and certain neurological diseases. Successfully expanding the range of indications for bevacizumab could open new market segments and stimulate revenue. 

Challenges/ Restraints

• Patent expiry and potential generic competition

Bevacizumab has limited patent exclusivity, and if the patents expire, it opens the door to potential generic competition. Generic versions of bevacizumab, also known as biosimilars, may enter the market at lower prices, challenging incumbent drugmakers for market share and profitability. Successfully navigating the competitive environment by introducing biosimilars is a major challenge for companies in the bevacizumab market. 

• High cost and limited affordability

Bevacizumab is a complex biological drug with high production costs. As a result, medicines are expensive, making them unaffordable for a large part of the population, especially in developing and low-income countries. The high cost of bevacizumab may limit its availability and adoption, thus hindering market growth. 

• Stringent regulatory requirements

The regulatory processes and requirements for approval of bevacizumab and other biologics can be rigorous and time-consuming. Regulatory approval from different authorities in multiple countries can be complex and expensive. Regulatory challenges may delay market entry and limit the availability of bevacizumab, affecting the growth potential of this market. 

The global Bevacizumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Bevacizumab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, the European Medicines Agency (EMA) approved the first biosimilar of bevacizumab for the treatment of multiple types of cancer. The availability of biosimilars contributes to increased competition in the market and has the potential to enhance patient access to bevacizumab therapy.

• In 2020, the U.S. Food and Drug Administration (FDA) approved bevacizumab in combination with chemotherapy as a treatment option for patients with advanced hepatocellular carcinoma (liver cancer). Ongoing clinical trials and research also evaluate the use of bevacizumab in combination with other therapies and its potential in different types of cancers and non-cancerous conditions. 

Global Bevacizumab Market Scope

This market is segmented on the basis of diseases, brand name, Dosage, application, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diseases

• Cancer
• Eye diseases

Brand Name

• Avastin
• Mvasi
• Zirabev
• Others

Dosage

• 100 mg
• 400 mg

Application

• Non squamous non-small cell lung cancer
• Recurrent glioblastoma
• Cervical cancer
• Colorectal cell cancer
• Ovarian cancer
• Proliferative diabetic retinopathy
• Malignant glioma
• Neurofibromatosis
• Pancreatic cancer
• Others

End User

• Hospitals
• Cancer supportive centres
• Home healthcare
• Academic and research institutes
• Others

Distribution channel

• Direct tender
• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
• Others

Global Bevacizumab Market Regional Analysis/Insights

The global bevacizumab market is analysed, and market size insights and trends are provided by country, diseases, brand name, Dosage, application, end-users, and distribution channel as referenced above.

The countries covered in this market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

Europe accounts for the largest market share due to the increased consumption of bevacizumab to treat various types of cancer.   

Asia-Pacific is expected to account for the largest market share over the coming years for the market due to increasing prevalence and growing healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Bevacizumab market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Bevacizumab Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Genentech (U.S.)
• Amgen (U.S.)
• Pfizer Inc. (U.S.)
• Allergan (Ireland)
• Biocon (India)
• Reliance Life Sciences (India)
• Beacon Pharmaceuticals Limited (Bangladesh)
• Celgene Corporation (U.S.)
• Mylan Inc, (U.S.)
• Dr. Reddy’s Laboratories Ltd (India)
• Eli Lilly and Company (India)
• BioXpress Therapeutics (Switzerland)
• Teva Pharmaceutical industries Ltd. (Isarel)
• CELLTRION INC. (South Korea)
• mAbxience (Switzerland)
• Samsung Bioepis (China)
• FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. (Japan)
• Hetero Drugs (U.S.)
• AryoGen Pharmed (Iran)
• Zydus Cadila (India)

SKU-59263